Form 4: Aquestive CEO Daniel Barber Reports Stock Withholding
Statement of Changes in Beneficial Ownership
Aquestive Therapeutics CEO Daniel Barber reported the withholding of 335,922 shares to satisfy tax obligations related to vested performance stock units.
Summary
- CEO Daniel Barber disposed of 335,922 shares of Aquestive Therapeutics common stock.
- The transaction occurred on May 5, 2026, at a price of $4.18 per share.
- The disposal was a mandatory tax withholding event related to the vesting of Performance Stock Units (PSUs).
- Following this transaction, the CEO retains beneficial ownership of 668,831 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax settlement rather than a discretionary sale of stock.
Positives
- The transaction reflects the vesting of performance-based equity, indicating the achievement of pre-defined corporate or individual performance milestones.
Negatives
- The transaction results in a reduction of the CEO's direct shareholding in the company.
Risks
- None identified; this is a routine administrative transaction related to tax obligations.
Future Outlook
No forward-looking guidance provided in this filing.
Industry Context
StockSavvy.ai notes that tax withholding transactions are standard corporate governance procedures for executives receiving equity-based compensation and do not typically signal a change in management sentiment regarding the company's future performance.
Comparison to Industry Standards
- The transaction follows standard SEC reporting requirements for executive equity vesting.
- The use of 'sell-to-cover' or withholding shares for taxes is a common practice among publicly traded pharmaceutical and biotech firms.
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a standard tax-related equity settlement.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/05/2026 | Date of the transaction involving the withholding of shares. |
| 05/07/2026 | Date the Form 4 was signed and filed with the SEC. |
Keywords
Aquestive Therapeutics, AQST, Insider Trading, Form 4, Executive Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.